Primary Sjögren’s syndrome is an autoimmune disease characterized by lymphoid infiltration of the salivary and lacrimal glands leading to dry mouth and eyes. Sjögren’s syndrome is one of the most common chronic systemic* autoimmune diseases.
OSE-127/S95011, a monoclonal antibody, is being developed in partnership with OSE Immunotherapeutics. Servier is conducting a randomized, double-blind, placebo-controlled, phase 2a study designed to evaluate the efficacy and tolerance of this antibody in primary Sjögren’s syndrome.
The patient enrollment – 48 patients in total – has been completed. Results are expected during 2023.
«We are humbled with the progress of this clinical study and look forward to announcing the initial results in the coming year. Primary Sjögren’s syndrome, one of the most common systemic autoimmune diseases, is a disease with significant unmet need and we are grateful to the patients for their participation in this study».Patricia Belissa-Mathiot, Servier’s Director of clinical development and R&D Chief Medical Officer.
An open innovation culture
Servier favors open collaboration to accelerate the development of therapeutic solutions for the benefit of patients. With the conviction that collaboration and constant dialogue between healthcare players create the best conditions for fast-paced innovation oriented to meet patient needs, Servier continues to broaden and diversify its network of R&D partners – academic structures, pharma groups, and biotechs.
* Systemic: refers to a disease or treatment that affects the entire body.